Identifying heterogeneous subtypes of KRAS mutant NSCLC tumors with varying co-mutations and associations with TMB and PD-L1 may better inform the responsiveness of these tumors to ICIs. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.